CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally
Corcept Therapeutics (CORT) shares rose 7% to their highest 2026 levels after announcing plans to resubmit its NDA for Relacorilant, a Cushing’s syndrome treatment, following positive FDA discussions. The FDA rejected the initial filing in December, citing insufficient effectiveness data. The company expects a PDUFA date six months post-submission. CORT shares are down 27% year-to-date, with retail sentiment remaining bearish.
How this was made
The 30-second read
Why it matters
The resubmission removes a major regulatory hurdle, likely supporting near‑term price appreciation.
Market read
First‑report of NDA resubmission provides fresh catalyst for CORT, driving a notable price move.
What to watch
Potential competition from other Cushing's syndrome therapies and the cost of a second FDA review.
Background
Corcept's Relacorilant targets hypercortisolism, a rare endocrine disorder with unmet medical need.
Ticker impact
Corcept Therapeutics announced it will resubmit its NDA for Relacorilant to the FDA, prompting a >7% price rise.
Expect continued short‑term rally as investors price in potential approval.
NDA resubmission after prior rejection signals progress; market already reacted positively with a 7% jump.
Market effects
Biotech sector may see modest lift as FDA resubmissions gain attention.
U.S. biotech stocks could benefit from renewed investor optimism.
Limited to U.S. and international investors tracking FDA pipeline developments.
Counterpoint
If the FDA still finds efficacy data insufficient, the stock could reverse sharply.
Key entities
- ExecutiveJoseph K. Belanoff
CEO of Corcept Therapeutics, quoted on NDA resubmission plans.
- RegulatorFDA
U.S. Food and Drug Administration, the agency reviewing the NDA.